Emphysema is a progressive lung disease characterized by destruction of the alveoli. The airflow obstruction, hyperinflation and impaired gaseous exchange combine to cause enormous morbidity and significant mortality. There are very limited therapeutic options and only smoking cessation and the appropriate prescription of long-term oxygen therapy have been shown to alter the course of the disease.1 Consequently, any therapeutic intervention that will improve symptoms is to be welcomed. In 1954, Otto Brantigan suggested that much of the breathlessness of emphysema was the result of hyperinflation that caused loss of circumferential pull on the bronchioles and airway collapse on expiration. He pioneered a novel operation that he called lung volume reduction, which aimed to remove damaged lung, reduce the intrathoracic volume and restore the circumferential forces on the small airways. This, he predicted, would result in an imgrovement in respiratory function and breathlessness. The initial reports were encouraging and, although they lacked any measurements of physiology, the authors commented that most patients noted an improvement in symptoms and that in some cases this improvement was sustained for eight years.2 Unfortunately, the early mortality associated with this operation was 16% and it quickly fell out of favour as the risks considerably outweighed any potential benefit.
In the mid-1990s Joel Cooper pioneered a revival of 'pneumectomy' or volume reduction. The great advances in postoperative care and in surgical techniques to staple emphysematous lung, combined with careful patient selection, resulted in a significant reduction in mortality. Cooper This salutary observation and the enormous cost of thoracic surgery applied pressure on the funding authorities, physicians and surgeons to partake in clinical trials to assess the efficacy of lung volume reduction surgery.
The first randomized controlled trials involved small numbers of patients with cross-over from the medical to the surgical arm after three or six months.' 12 They suggested that lung volume reduction surgery improved spirometry, exercise capacity and quality of life, but many questions were left unanswered. Should we only choose patients with upper lobe emphysema? How long does any benefit last? What is the best surgical approach (median sternotomy or video-assisted thoracoscopic surgery, unilateral or bilateral approach, apical or basal resections), is the operation suitable for individuals with PiZ cx 1-antitrypsin deficiency and what is the risk-benefit for the patient and the cost-benefit for the healthcare provider? The National Emphysema Treatment Trial was established to try and answer some of these questions. The study started in January 1998 and aimed to recruit 2500 individuals with emphysema from 17 centres over 4.5 years. The inclusion criteria were broad (HRCT evidence of bilateral emphysema, FEV1 < 45% predicted and residual volume > 150% predicted) with the primary endpoints being survival and maximum exercise capacity. 13 In total, 3777 individuals with severe emphysema were screened and 1218 were enrolled into the study. All individuals were assessed with HRCT scans, radio-nucleotide scans, health-related quality of life questionnaires and maximal exercise capacity was determined. They all underwent 6-10 weeks of pulmonary rehabilitation and 608 were randomized to receive lung volume reduction 10 11, 18 So where are we now? There is good evidence that patients with upper lobe emphysema and poor exercise capacity benefit from lung volume reduction surgery. However, patients should not be too unwell as they have an increased mortality.14 We still do not know how long any benefit will last and there is conflicting evidence for the role of this operation in individuals with PiZ otantitrypsin deficiency. 19, 20 Questions still remain about the role of unilateral lung volume reduction 22 and any operative approach is only suitable for a small proportion of individuals with emphysema. Alternative approaches are being developed and there is preliminary evidence to support the use of endobronchial valves that may reduce lung volume without resecting lung.23 In summary, we have come a long way since Brantigan first suggested reducing the volume of the lung to treat emphysema. There is now clear evidence that it is effective in a proportion of individuals with emphysema, but questions still remain about longterm efficacy and cost-effectiveness and its use in individuals with PiZ a 1-antitrypsin deficiency.
